IP Library Granted Patent US 7,427,603
Granted Patent B2
US 7,427,603 · App. 10/528,808 · Granted Sep 23, 2008

Method of enhancing proliferation and/or hematopoietic differentiation of stem cells

Assignee: The Children's Medical Center Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,427,603
App. No.
10/528,808
Granted
Sep 23, 2008
Kind
B2
Abstract

The present invention provides a method for enhancing the proliferation and/or hematopoietic differentiation and/or maintenance of mammalian stem cells. The method is useful for generating expanded populations of hematopoietic stem cells (HSCs) and thus mature blood cell lineages. This is desirable where a mammal has suffered a decrease in hematopoietic or mature blood cells as a consequence of disease, radiation or chemotherapy. The method of the present invention comprises increasing the intracellular level of a cdx in stem cells, including hematopoietic stem cells, in culture, either by providing an exogenous cdx protein to the cell, or by introduction into the cell of a genetic construct encoding a cdx. The cdx is selected from the cdx family and includes cdx1, cdx2, or cdx4. The cdx may be a wild type protein appropriate for the species from which the cells are derived, or a mutant form of the protein.

Claims (25)

1. A method for enhancing hematopoietic differentiation of a mammalian stem cell comprising, transfecting said stem cells in an in vitro culture medium with an exogenous nucleic acid comprising a cdx4 coding sequence operably linked to a promoter.

2. The method of claim 1 , wherein the stem cell is a hematopoietic stem cell.

3. The method of claim 1 , wherein the cell is a CD34+ cell.

4. The method of claim 1 , wherein the cell is autologous.

5. The method of claim 1 , wherein the cell is obtained from a human.

6. The method of claim 5 , wherein the human is suffering from, or is susceptible to, decreased blood cell levels.

7. The method of claim 6 , wherein the decreased blood cell levels are caused by chemotherapy, radiation therapy, bone marrow transplantation therapy or congenital anemia.

8. The method of claim 1 , wherein the exogenous nucleic acid is a retroviral vector.

9. The method of claim 1 , wherein the exogenous nucleic acid is an episomal vector.

10. The method of claim 1 , wherein the stem cell is an embryonic stem cell.

11. A method of treating a mammal in need of improved hematopoietic capability, comprising the steps of: (a) removing hematopoietic stem cells from the mammal; (b) transfecting said stem cells with exogenous nucleic acid comprising a cdx4 sequence; (c) culturing said transfected stem cells to form an expanded population of stem cells; and (d) returning said expanded cells to the mammal, whereby hematopoietic capability is improved.

12. The method of claim 11 , wherein the mammal is a human.

13. The method of claim 11 , wherein the exogenous nucleic acid is a retroviral vector.

14. A method for enhancing hematopoietic differentiation of a mammalian stem cell comprising, treating said stem cells by addition in an in vitro culture medium of an exogenous cdx4 peptide.

15. The method of claim 14 , wherein the stem cell is a hematopoietic stem cell.

16. The method of claim 14 , wherein the cell is a CD34+ cell.

17. The method of claim 14 , wherein the cell is autologous.

18. The method of claim 14 , wherein the cell is obtained from a human.

19. The method of claim 18 , wherein the human is suffering from, or is susceptible to, decreased blood cell levels.

20. The method of claim 19 , wherein the decreased blood cell levels are caused by chemotherapy, radiation therapy, bone marrow transplantation therapy, or congenital anemia.

21. The method of claim 14 , wherein the stem cell is an embryonic stem cell.

22. The method of claim 14 , wherein said cdx4 is genetically fused to a transport moiety.

23. The method of claim 22 , wherein said transport moiety is a fragment of HIV tat protein.

24. A method of treating a mammal in need of improved hematopoietic capability, comprising the steps of: (a) removing hematopoietic stem cells from the mammal; (b) treating said stem cells by administration of exogenous cdx4 peptide; (c) culturing said stem cells to form an expanded population of stem cells; and (d) returning said expanded cells to the mammal, whereby hematopoietic capability is improved.

25. The method of claim 24 , wherein the mammal is a human.

Assignments (4)
CONFIRMATORY LICENSE Recorded Apr 24, 2019
From: BOSTON CHILDREN'S HOSPITAL
To: NIH-DEITR
Reel/Frame 048986/0978 →
CONFIRMATORY LICENSE Recorded Jun 18, 2010
From: CHILDREN'S HOSPITAL (BOSTON)
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024555/0834 →
CONFIRMATION OF ASSIGNMENT Recorded Dec 15, 2006
From: HOWARD HUGHES MEDICAL INSTITUTE THROUGH LEONARD I. ZON
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 018642/0301 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2005
From: ZON, LEONARD I.; DAVIDSON, ALAN J.; DALEY, GEORGE Q.
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 016246/0563 →
Continuity (2)
Provisional Application 6041381600 · Sep 26, 2002
Related Publication 20050221487A1 · Oct 6, 2005